Systematic review of 25 studies (1,587 patients) with meta-analysis of placebo-controlled RCTs: anti-CGRP antibodies improved ≥50% response at 4 weeks in episodic cluster headache (OR 1.65) but showed no significant effect in chronic cluster headache (OR 1.07).
Meta-analysisn = 1,587
Kolakowski et al. Efficacy and effectiveness of anti-CGRP monoclonal antibodies treatment in the prevention of cluster headache attacks: A systematic review and meta-analysis